8-K: Cellectar Biosciences Secures $35M in Registered Direct Offering

Cellectar Biosciences announced a registered direct offering and concurrent private placement raising approximately $35 million to fund its Phase 3 trial for iopofosine I 131.

Summary

• Cellectar Biosciences, Inc. announced on May 4, 2026, the closing of a registered direct offering and a concurrent private placement, raising gross proceeds of approximately $35 million before deducting placement agent fees and offering expenses.
• The net proceeds are intended for working capital and general corporate purposes, specifically to support the initiation of a Phase 3 trial of iopofosine I 131 for Waldenström's macroglobulinemia (WM) patients.
• The offering included the sale of 1,618,053 registered shares of common stock, 2,116,887 unregistered shares of common stock, pre-funded warrants to purchase 9,471,086 shares of common stock, and milestone-based warrants (Tranche A, B, and C) for 13,206,026 shares of common stock.
• Certain members of the executive management team participated in the private placement at a purchase price of $2.88 per share and accompanying warrants.
• Nantahala Capital Management, LLC, a significant investor, secured a board designation right, with the company agreeing to appoint a director selected by Nantahala, subject to board approval and independence requirements.
• The company also entered into a placement agency agreement with Ladenburg Thalmann & Co. Inc. for the offering, paying fees and warrants for their services.
• The offering closed on May 6, 2026.
• The company reported positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial for iopofosine I 131, showing an 83.6% Overall Response Rate (ORR) and a 61.8% Major Response Rate (MRR).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously positive development. While the capital raise and positive clinical data are strong positives, the significant dilution and the inherent risks of clinical-stage drug development temper the overall sentiment.

Positives

• Successfully raised approximately $35 million through a registered direct offering and concurrent private placement.
• Secured funding to advance the Phase 3 trial of iopofosine I 131 for Waldenström's macroglobulinemia.
• Received positive clinical trial data for iopofosine I 131, with an 83.6% ORR and 61.8% MRR in a Phase 2b trial.
• Strengthened investor relations with a board designation right granted to Nantahala Capital Management, LLC.
• The offering was completed efficiently, closing on May 6, 2026.

Negatives

• The issuance of a significant number of shares and warrants could lead to substantial dilution for existing shareholders.
• The company is still in clinical development stages, with iopofosine I 131 not yet approved by the FDA.
• The company is reliant on future milestones for the exercise of certain warrants, introducing uncertainty.
• The company incurred significant placement agent fees and expenses, impacting the net proceeds.

Risks

• The success of the Phase 3 trial for iopofosine I 131 is critical and subject to clinical trial risks.
• Regulatory approval from the FDA for iopofosine I 131 is not guaranteed.
• The company's ability to manage its cash burn and achieve profitability remains a significant risk.
• Future dilution from the exercise of outstanding warrants could negatively impact share price.
• Market conditions and investor sentiment could affect the company's ability to raise future capital.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including supporting the initiation of a Phase 3 trial of iopofosine I 131 for Waldenström's macroglobulinemia patients. The milestone warrants are exercisable upon stockholder approval and are callable by the company upon the achievement of certain events, with exercise prices and terms dependent on the specific tranche (A, B, or C).

Industry Context

StockSavvy.ai notes that this financing round is crucial for Cellectar Biosciences as it advances its lead candidate, iopofosine I 131, into a pivotal Phase 3 trial. The positive Phase 2b data is encouraging, but the company remains in a high-risk, high-reward phase of development common in the biotechnology sector. The capital raise, while substantial, also brings significant dilution concerns, a frequent challenge for companies at this stage.

Corporate Governance

Related Party Transactions

• Certain members of the executive management team participated in the private placement at a purchase price of $2.88 per share and accompanying milestone-based warrants.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares and warrants.
• Investors in the offering gain equity and potential upside from the company's clinical development progress.
• The funding provides operational stability and supports the advancement of the company's lead drug candidate.

Next Steps

• Initiate Phase 3 trial of iopofosine I 131 for Waldenström's macroglobulinemia patients.
• File a registration statement for the resale of unregistered shares and warrant shares by May 19, 2026.
• Obtain stockholder approval for the exercise of common warrants.
• Nantahala Capital Management, LLC to designate a board member by June 5, 2026.

Key Dates

Recommendation

The company has secured crucial funding to advance its lead drug candidate into Phase 3 trials, supported by positive Phase 2b data. However, the significant dilution from the equity raise and the inherent risks associated with clinical-stage biotechnology companies warrant a 'hold' recommendation. Investors should monitor the progress of the Phase 3 trial and regulatory approvals closely.

Keywords

Cellectar Biosciences, Registered Direct Offering, Private Placement, Iopofosine I 131, Waldenström's macroglobulinemia, Clinical Trial, Warrants, Financing